141 related articles for article (PubMed ID: 22462761)
1. EC145: a novel targeted agent for adenocarcinoma of the lung.
Pribble P; Edelman MJ
Expert Opin Investig Drugs; 2012 May; 21(5):755-61. PubMed ID: 22462761
[TBL] [Abstract][Full Text] [Related]
2. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
Edelman MJ; Harb WA; Pal SE; Boccia RV; Kraut MJ; Bonomi P; Conley BA; Rogers JS; Messmann RA; Garon EB
J Thorac Oncol; 2012 Oct; 7(10):1618-21. PubMed ID: 22982661
[TBL] [Abstract][Full Text] [Related]
3. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
[TBL] [Abstract][Full Text] [Related]
4. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
Ambrosio AJ; Suzin D; Palmer EL; Penson RT
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
[TBL] [Abstract][Full Text] [Related]
5. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Graybill WS; Coleman RL
Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Reddy JA; Dorton R; Westrick E; Dawson A; Smith T; Xu LC; Vetzel M; Kleindl P; Vlahov IR; Leamon CP
Cancer Res; 2007 May; 67(9):4434-42. PubMed ID: 17483358
[TBL] [Abstract][Full Text] [Related]
7. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
[TBL] [Abstract][Full Text] [Related]
8. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
Leamon CP; Reddy JA; Klein PJ; Vlahov IR; Dorton R; Bloomfield A; Nelson M; Westrick E; Parker N; Bruna K; Vetzel M; Gehrke M; Nicoson JS; Messmann RA; LoRusso PM; Sausville EA
J Pharmacol Exp Ther; 2011 Feb; 336(2):336-43. PubMed ID: 20978169
[TBL] [Abstract][Full Text] [Related]
9. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
10. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients.
Li J; Sausville EA; Klein PJ; Morgenstern D; Leamon CP; Messmann RA; LoRusso P
J Clin Pharmacol; 2009 Dec; 49(12):1467-76. PubMed ID: 19837906
[TBL] [Abstract][Full Text] [Related]
12. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
[TBL] [Abstract][Full Text] [Related]
14. Clinical translation of folate receptor-targeted therapeutics.
Teng L; Xie J; Teng L; Lee RJ
Expert Opin Drug Deliv; 2012 Aug; 9(8):901-8. PubMed ID: 22663189
[TBL] [Abstract][Full Text] [Related]
15. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
16. Imaging sites of infection using a 99mTc-labeled folate conjugate targeted to folate receptor positive macrophages.
Henne WA; Rothenbuhler R; Ayala-Lopez W; Xia W; Varghese B; Low PS
Mol Pharm; 2012 May; 9(5):1435-40. PubMed ID: 22468849
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent.
Reddy JA; Nelson M; Dircksen C; Vetzel M; Johnson T; Cross V; Westrick E; Qi L; Hahn S; Santhapuram HK; Parham G; Wang K; Vaughn JF; Felten A; Pugh M; Lu J; Klein P; Vlahov IR; Leamon CP
Sci Rep; 2020 Jul; 10(1):12772. PubMed ID: 32728172
[TBL] [Abstract][Full Text] [Related]
18. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F
Eur J Cancer; 2012 Sep; 48(13):2054-65. PubMed ID: 21937219
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.
Chen Q; Meng X; McQuade P; Rubins D; Lin SA; Zeng Z; Haley H; Miller P; González Trotter D; Low PS
Mol Pharm; 2016 May; 13(5):1520-7. PubMed ID: 27054811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]